Nature Biomedical Engineering最新文献_第2页

Targeting myeloid cell-mediated fibrosis through FAK. 通过FAK靶向髓细胞介导的纤维化。

IF 28.1 1区医学

Nature Biomedical Engineering Pub Date : 2025-10-21 DOI: 10.1038/s41551-025-01482-w

Maya Ezzo,Boris Hinz

引用次数: 0

Engineering a macromolecular JAK inhibitor for treating acute inflammation and endotoxaemia. 设计用于治疗急性炎症和内毒素血症的大分子JAK抑制剂。

IF 28.1 1区医学

Nature Biomedical Engineering Pub Date : 2025-10-17 DOI: 10.1038/s41551-025-01521-6

Min Zhou,Yan Wang,Bin Yang,Yang Zhang,Ling Zhong,Kaiyao Hu,Wendan Pu,Gaoxing Luo,Jianxiang Zhang

{"title":"Engineering a macromolecular JAK inhibitor for treating acute inflammation and endotoxaemia.","authors":"Min Zhou,Yan Wang,Bin Yang,Yang Zhang,Ling Zhong,Kaiyao Hu,Wendan Pu,Gaoxing Luo,Jianxiang Zhang","doi":"10.1038/s41551-025-01521-6","DOIUrl":"https://doi.org/10.1038/s41551-025-01521-6","url":null,"abstract":"Uncontrolled and sustained inflammation is inextricably associated with the pathogenesis of numerous diseases. However, there is still demand for effective and safe anti-inflammatory therapies. Here we report a potent anti-inflammatory macromolecular therapy named HPL, created by conjugating polyethylene glycol and luminol onto a multivalent and hydrolysable cyclic structure. Leveraging its amphiphilic nature, HPL can spontaneously self-assemble into micelles capable of targeting inflamed tissues and localizing in inflammatory cells. In mice with acute lung, kidney and liver injuries, as well as endotoxaemia, HPL shows anti-inflammatory effects that rivals or surpasses those of two commonly used anti-inflammatory drugs. HPL micelles can act as bioactive and inflammation-responsive carriers for site-specific delivery to release anti-inflammatory drugs. Mechanistically, HPL exerts its anti-inflammatory activity mainly by inhibiting the IL-6/JAK2/STAT3 signalling pathway. HPL shows favourable safety profiles in mice at doses at least 5-fold higher than those used in therapeutic studies. These findings suggest that HPL holds great promise as a highly potent, cost-effective and safe JAK2 inhibitor for treating various diseases associated with inflammation.","PeriodicalId":19063,"journal":{"name":"Nature Biomedical Engineering","volume":"16 1","pages":""},"PeriodicalIF":28.1,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145311252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autonomous ultrasound with UltraBot 使用UltraBot的自主超声波。

IF 26.8 1区医学

Nature Biomedical Engineering Pub Date : 2025-10-17 DOI: 10.1038/s41551-025-01546-x

Rita Strack

引用次数: 0

Managing haemodynamic instability in spinal cord injury 脊髓损伤血流动力学不稳定的处理。

IF 26.8 1区医学

Nature Biomedical Engineering Pub Date : 2025-10-17 DOI: 10.1038/s41551-025-01547-w

Sadra Bakhshandeh

引用次数: 0

Next-generation anti-Aβ antibodies show promise in a mouse model of Alzheimer disease 下一代抗a β抗体在阿尔茨海默病小鼠模型中显示出希望。

IF 26.8 1区医学

Nature Biomedical Engineering Pub Date : 2025-10-17 DOI: 10.1038/s41551-025-01540-3

Diana Romero

引用次数: 0

Predicting vaccine effectiveness 预测疫苗的有效性。

IF 26.8 1区医学

Nature Biomedical Engineering Pub Date : 2025-10-17 DOI: 10.1038/s41551-025-01539-w

Michael Attwaters

引用次数: 0

The ever-changing communication of scientific discovery 不断变化的科学发现交流。

IF 26.8 1区医学

Nature Biomedical Engineering Pub Date : 2025-10-17 DOI: 10.1038/s41551-025-01551-0

引用次数: 0

Deep-learning-based HER2 status assessment from multimodal breast cancer data predicts neoadjuvant therapy response. 基于深度学习的多模态乳腺癌HER2状态评估预测新辅助治疗反应。

IF 28.1 1区医学

Nature Biomedical Engineering Pub Date : 2025-10-17 DOI: 10.1038/s41551-025-01495-5

Jiadong Zhang,Yonghao Li,Zheren Li,Zhiming Cui,Pinxiong Li,Jun Li,Zhen Li,Yu Xie,Kannie W Y Chan,Qinrong Zhang,Zhenhui Li,Dinggang Shen

{"title":"Deep-learning-based HER2 status assessment from multimodal breast cancer data predicts neoadjuvant therapy response.","authors":"Jiadong Zhang,Yonghao Li,Zheren Li,Zhiming Cui,Pinxiong Li,Jun Li,Zhen Li,Yu Xie,Kannie W Y Chan,Qinrong Zhang,Zhenhui Li,Dinggang Shen","doi":"10.1038/s41551-025-01495-5","DOIUrl":"https://doi.org/10.1038/s41551-025-01495-5","url":null,"abstract":"Accurate assessment of human epidermal growth factor receptor 2 (HER2) status is crucial for effective breast cancer treatment planning and improved patient outcomes. Traditional needle biopsies, limited in tissue sampling, often lead to inaccurate assessments due to intratumoural heterogeneity. Here, to address this, we introduce the deep-learning-based HER2 multimodal alignment and prediction (MAP) model, which leverages pretreatment multimodal breast cancer images for a more comprehensive reflection of tumour characteristics and provides more accurate HER2 status prediction. We develop patient response MAP models to demonstrate the HER2 prediction performance of our model compared with needle biopsies from patients receiving neoadjuvant therapy. A large-scale multimodal breast cancer dataset from 4 centres, consisting of 14,472 images from 6,991 cases, is adopted in this study, and the results consistently demonstrate the superiority of our HER2 MAP model in predicting patient response. These findings highlight the substantial advantages of our HER2 predictions. Our study provides physicians with a crucial tool for informed clinical decisions and treatment plans, aiming to improve outcomes in patients with breast cancer.","PeriodicalId":19063,"journal":{"name":"Nature Biomedical Engineering","volume":"19 1","pages":""},"PeriodicalIF":28.1,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145311454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhibition of LARP4-mediated quiescence exit of naive CD4+ T cells ameliorates autoimmune and allergic diseases. 抑制larp4介导的初始CD4+ T细胞的静止退出可改善自身免疫性和过敏性疾病。

IF 28.1 1区医学

Nature Biomedical Engineering Pub Date : 2025-10-16 DOI: 10.1038/s41551-025-01514-5

Jian Zhou,Di Yang,Chao Han,Hui Dong,Shufeng Wang,Xiang Li,Jun Hu,Cui Wang,Jie Luo,Zhiyuan Wei,Taiping Liu,Shuai Xu,Chen Xu,Yiwei Zhang,Xian Wang,Yuanyu Deng,Baiqing Li,Ruihan Mao,Mingyang Zhang,Yi Sun,Xinyuan Zhou,Lilin Ye,Bing Ni,Jun Zhu,Juan Li,Jingbo Zhang,Tingting Zhao,Xiangmei Chen,Rong Lin,Yi Zhang,Yuzhang Wu,Yi Tian

{"title":"Inhibition of LARP4-mediated quiescence exit of naive CD4+ T cells ameliorates autoimmune and allergic diseases.","authors":"Jian Zhou,Di Yang,Chao Han,Hui Dong,Shufeng Wang,Xiang Li,Jun Hu,Cui Wang,Jie Luo,Zhiyuan Wei,Taiping Liu,Shuai Xu,Chen Xu,Yiwei Zhang,Xian Wang,Yuanyu Deng,Baiqing Li,Ruihan Mao,Mingyang Zhang,Yi Sun,Xinyuan Zhou,Lilin Ye,Bing Ni,Jun Zhu,Juan Li,Jingbo Zhang,Tingting Zhao,Xiangmei Chen,Rong Lin,Yi Zhang,Yuzhang Wu,Yi Tian","doi":"10.1038/s41551-025-01514-5","DOIUrl":"https://doi.org/10.1038/s41551-025-01514-5","url":null,"abstract":"Naive T cells are maintained under a quiescent state, and their exit from quiescence is a hallmark of antigen stimulation. Here we identify the RNA binding protein La-related protein 4 (LARP4) as an important checkpoint regulator of quiescence exit in naive CD4+ T cells. Conditional knockout of LARP4 in naive CD4+ T cells leads to an enhanced quiescence state and/or dampened quiescence exit due to altered stability of several messenger RNAs important for T-cell activation. The differentiation of naive CD4+ T cells into helper T-cell subsets is also impaired after conditional knockout, leading to ameliorated autoimmune and allergic responses. Lastly, we design a peptide inhibitor of LARP4 (LIPEP), and treatment with LIPEP could perfectly mimic LARP4 deficiency and alleviate the severity of autoimmune and allergic diseases in the corresponding mouse models. Our study reveals a link between RNA stability and CD4+ T-cell homeostasis/adaptive activation, highlighting the potential of LARP4 as a preventative and therapeutic target for autoimmune and allergic diseases although at quite high doses.","PeriodicalId":19063,"journal":{"name":"Nature Biomedical Engineering","volume":"20 1","pages":""},"PeriodicalIF":28.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level 在颗粒、转录物和蛋白质水平上靶向和跟踪mRNA脂质纳米颗粒。

IF 26.8 1区医学

Nature Biomedical Engineering Pub Date : 2025-10-16 DOI: 10.1038/s41551-025-01511-8

Diana D. Kang, Adam Marks, Judit Morla-Folch, Yizhou Dong, Brian D. Brown, Abraham J. P. Teunissen

{"title":"Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level","authors":"Diana D. Kang, Adam Marks, Judit Morla-Folch, Yizhou Dong, Brian D. Brown, Abraham J. P. Teunissen","doi":"10.1038/s41551-025-01511-8","DOIUrl":"10.1038/s41551-025-01511-8","url":null,"abstract":"Lipid nanoparticles (LNPs) are a versatile platform with numerous experimental, diagnostic and therapeutic applications. However, the high propensity of LNPs to accumulate in hepatocytes and antigen-presenting cells has largely limited their clinical use to vaccines and the treatment of liver diseases. In this Review, we describe established and emerging techniques for monitoring the in vivo behaviour of RNA-loaded LNPs (RNA-LNPs) and strategies for improved tissue and cell targeting that expand the applications of this technology. We discuss innovations in LNP chemistry and bioengineering, and exploiting synthetic biology to tailor the cellular expression of the mRNA cargo, including the use of microRNA target sites. We also review how modifications to the encoded protein can be used to control stability and subcellular localization of the payload. Lastly, we discuss how these techniques and strategies can accelerate the clinical translation of RNA-LNP drugs and improve therapeutic outcomes. This Review explores strategies for targeting and tracking RNA-LNP drugs, monitoring their in vivo behaviour, enhancing tissue-specific delivery, and using synthetic biology to control mRNA expression and protein localization.","PeriodicalId":19063,"journal":{"name":"Nature Biomedical Engineering","volume":"9 10","pages":"1591-1609"},"PeriodicalIF":26.8,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0